Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Observational

Chinese Cardiologists' Knowledge/Practices on Flu Vaccine for Chronic Coronary Syndrome

NCT06991088 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2025-06
Last updated
2025-06-04

Condition(s) studied

Chinese Cardiologists

Study summary

This long-term single-center cross-sectional study evaluates physicians' knowledge of influenza vaccination in CCS patients through collected feedback, while identifying knowledge gaps and misconceptions regarding vaccination. By analyzing factors influencing physicians' recommendation practices, it provides evidence to guide future educational and policy interventions. Ultimately, the study aims to enhance cardiologists' vaccination awareness, thereby optimizing CCS patient management and reducing influenza-associated complications and mortality.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: Cardiologists (licensed practitioners) with specialized knowledge of the association between influenza vaccination and cardiovascular diseases. Exclusion Criteria: * Physicians from non-cardiology specialties (e.g., surgery, general internal medicine \[including respiratory and gastroenterology departments\], emergency medicine). * Physicians unable to complete the questionnaire survey.

Primary outcome measure(s)

  • cognitive status — baseline and 1-year later
    Based on a survey on "Cardiologists' Knowledge and Behavior Regarding Influenza Vaccination for Patients with Chronic Coronary Syndrome in China," regular follow-up will be conducted. The scale scores will be further improved in subsequent research.
  • practical situation — baseline and 1-year later
    Based on a survey on "Cardiologists' Knowledge and Behavior Regarding Influenza Vaccination for Patients with Chronic Coronary Syndrome in China," regular follow-up will be conducted. The scale scores will be further improved in subsequent research.
  • attitude — baseline and 1-year later
    Based on a survey on "Cardiologists' Knowledge and Behavior Regarding Influenza Vaccination for Patients with Chronic Coronary Syndrome in China," regular follow-up will be conducted. The scale scores will be further improved in subsequent research.

Trial sites (1)

FacilityCityRegionStatus
MingWei Wang Hanzhou Zhejiang
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06991088 on ClinicalTrials.gov ↗ ← All trials in China